# Immunocore Holdings plc (IMCR) FY2026 Q2 Balance Sheet

- Company: Immunocore Holdings plc (IMCR)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001671927-26-000022
- Page: https://plicit.ai/financials/imcr/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/imcr-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,119,422,000 US dollars
- **Current assets**: 1,051,044,000 US dollars
- **Non-current assets**: 68,378,000 US dollars
- **Liabilities**: 699,624,000 US dollars
- **Current liabilities**: 235,198,000 US dollars
- **Non-current liabilities**: 464,426,000 US dollars
- **Equity**: 419,798,000 US dollars
- **Cash and cash equivalents**: 484,920,000 US dollars
- **Marketable securities**: 395,291,000 US dollars
- **Accounts receivable, net**: 95,350,000 US dollars
- **Prepaid expenses and other current assets**: 67,692,000 US dollars
- **Inventory, net**: 7,791,000 US dollars
- **Operating lease right of use assets, net**: 37,020,000 US dollars
- **Other non-current assets**: 18,495,000 US dollars
- **Property and equipment, net**: 12,863,000 US dollars
- **Accrued expenses and other current liabilities**: 206,400,000 US dollars
- **Accounts payable**: 26,319,000 US dollars
- **Operating lease liabilities, current**: 1,906,000 US dollars
- **Deferred revenue, current**: 573,000 US dollars
- **Interest-bearing loans and borrowings**: 394,206,000 US dollars
- **Operating lease liabilities, non-current**: 38,847,000 US dollars
- **Accrued expenses, non-current**: 26,883,000 US dollars
- **Deferred revenue, non-current**: 4,490,000 US dollars
- **Additional paid-in capital**: 1,273,101,000 US dollars
- **Ordinary shares (voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,303 and £149,633 shares as of June 30, 2026 and December 31, 2025, respectively, and 51,480,159 and 50,689,271 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.**: 138,000 US dollars
- **Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of June 30, 2026 and December 31, 2025.**: 1,000 US dollars
- **Accumulated deficit**: negative 819,112,000 US dollars
- **Accumulated other comprehensive loss**: negative 34,330,000 US dollars
- **Gross equity (calculated)**: 1,273,240,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.